GSM6454749
— · F
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- F
- subtype
- F
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.580
- MYC_TARGETS_V1+0.570
- E2F_TARGETS+0.560
- G2M_CHECKPOINT+0.500
- OXIDATIVE_PHOSPHORYLATION+0.320
- DNA_REPAIR+0.270
- INTERFERON_ALPHA_RESPONSE+0.260
- SPERMATOGENESIS+0.190
- UNFOLDED_PROTEIN_RESPONSE+0.160
- MTORC1_SIGNALING+0.140
Top 10 suppressed
- ANGIOGENESIS-0.500
- APICAL_SURFACE-0.500
- COAGULATION-0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- APICAL_JUNCTION-0.460
- ESTROGEN_RESPONSE_LATE-0.410
- ESTROGEN_RESPONSE_EARLY-0.390
- NOTCH_SIGNALING-0.390
- CHOLESTEROL_HOMEOSTASIS-0.380
- TNFA_SIGNALING_VIA_NFKB-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518219 | — | E | 0.929 |
| 2 | BS_8GW1TMV2 | medulloblastoma | — | 0.899 |
| 3 | BS_TW8DQH8J | medulloblastoma | — | 0.899 |
| 4 | SRR2016966 | — | — | 0.898 |
| 5 | TCGA-85-A510-01A-11R-A26W-07 | — | cohortA3 | 0.891 |
| 6 | TCGA-22-5481-01A-31R-1949-07 | — | cohortMD1 | 0.889 |
| 7 | TCGA-HN-A2NL-01A-11R-A18M-07 | — | E | 0.887 |
| 8 | BS_DFGS950G | high-grade glioma | — | 0.879 |
| 9 | TCGA-34-5231-01A-21R-1820-07 | — | cohortSQ2 | 0.878 |
| 10 | TCGA-AR-A24H-01A-11R-A169-07 | — | B | 0.877 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.580 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.570 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.260 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.140 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.120 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.050 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.040 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.010 | Inavolisib | — uncovered |